资源描述:
《调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效观察.doc》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效观察【摘耍】目的:探讨常规分割调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效。方法:选择2011年10月-2013年10月门诊和住院治疗的高龄食管癌患者53例。根据治疗模式不同,分为同步组和对照组,同步组采用调强放射治疗同步替吉奥治疗,对照组采用单纯调强放射治疗。结果:同步组较对照组的副反应略高,但差异无统计学意义(P>0.05);同步组和对照组患者总有效率分别达到84.00%和57.14%,差异有统计学意义(P=0・033);同步组和对照组患者12个月随访期内的中位无进展生存期分别为10.84个月和9.36个月,差异有统计学意义(P二0.04
2、4),同步组和对照组患者的1年生存率分别为88.0%和85.7%,差界无统计学意义(P=0・75)。结论:调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效肯定。【关键词】调强放疗;替吉奥;食管癌中图分类号R735.1文献标识码A文章编号1674-6805(2015)9-0004-03ClinicalAnalysisofElderlyEsophagealCancerPatientsTre且tedwithIntensityModulatedRadiationTherapyandTegafurGimeracilOteracilPotassiumCapsule/WANGWu-long,WANGChu
3、n-lei,YUBai-qing,etal.//ChineseandForeignMedicalResearch,2015,13(9):4-6[Abstract]Objective:Tostudytheclinicalan且lysisofelderlyesophagealcancerpatientstreatedwithintensitymodulatedradiationtherapy(IMRT)andTegafurGimeracilOteracilPotassiumCapsule.Method:53elderlyesophagealcancerpatientsfromOctober20
4、11toOctober2013wereselected.Accordingtothedifferenttreatmentmodalities,theyweredividedintothesynchronouschemotherapygroupandthecontrolgroup,thesynchronouschemotherapygroupwastreatedwithIMRTandTegafurGimeracilOteracilPotassiumCapsule,thecontrolgroupwastreatedwithIMRT.Result:Thesideeffectsofthesynch
5、ronouschemotherapygroupwashigherthanthatofthecontrolgroup,butthedifferencehadnosignificantdifferencebetweentwogroups(P>0.05);thetotaleffectiverateofthesynchronouschemotherapygroupwas84.00%,thecontrolgroupwas57.14%,therewasstatisticallysignificantdifference(P二0.033),themedianprogressionfreesurvival
6、ofthesynchronouschemotherapygroupandcontrolgroupwere10.84monthsand9.36months,therewasstatisticallysignificantdifference(P二0.044),thesurvivalrateinoneyearofthesynchronouschemotherapygroupandcontrolgroupwere88.0%and85.7%,therewasnostatisticallysignificantdifference(P二0.75)・Conclusion:Effectivenessof
7、elderlyesophagealcancerpatientstreatedwithTMRTandTegafurGimeraci1OteracilPotassiumCapsuleisdefinite.【Keywords]Intensitymodulatedradiationtherapy;TegafurGimeracilOteracilPotassiumCapsule;EsophagealcancerFirst-auth